Prosecution Insights
Last updated: October 02, 2026
Application No. 18/779,403

TENDON REPAIR IMPLANT AND METHOD OF IMPLANTATION

Non-Final OA §DP
Filed
Jul 22, 2024
Priority
Jun 15, 2015 — provisional 62/175,829 +4 more
Examiner
BARIA, DINAH N
Art Unit
Tech Center
Assignee
Rotation Medical Inc.
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
6m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
473 granted / 649 resolved
+12.9% vs TC avg
Strong +28% interview lift
Without
With
+28.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
43 currently pending
Career history
694
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
38.9%
-1.1% vs TC avg
§102
16.6%
-23.4% vs TC avg
§112
32.7%
-7.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 649 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement Applicant should note that the large number of references in the attached IDS have been considered by the examiner in the same manner as other documents in Office search files are considered by the examiner while conducting a search of the prior art in a proper field of search. See MPEP 609.05(b). Applicant is requested to point out any specific references in the IDS which they believe may be of particular relevance to the instant claimed invention in response to this office action. Claim Objections Claims 12 and 15 are objected to because of the following informalities: line 3 of claim 12 states “the first sheet-like component and configured to have a first initial tensile…” (emphasis added), however it is though the word “and” was added in error, since the statement does not make sense; it is suggested the word “and” be deleted to correct this issue. Additionally, lines 1-2 of claim 15 states “about 10% to 50% the load of the tendon…”, however this statement is found to be grammatically incorrect; it is suggested the word “of” be added between the words “50%” and “the”, on line 1, to correct this issue. Appropriate correction is required. Applicant is advised that should claim 2 be found allowable, claim 9 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-4, 7-9, 12 and 13 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 18-21 of U.S. Patent No. 10,265,156; and claims 1, 4, 7, 8 and 20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 15 and 16 of U.S. Patent No. 10,888,415. Although the claims at issue are not identical, they are not patentably distinct from each other because all sets of claims disclose a tendon repair implant comprising a first sheet-like component having a first porosity and configured to have a first initial tensile modulus, in a range of about 5 megapascals (MPa) to 50 MPa; and a second sheet-like component having a second porosity and configured to have a second initial tensile modulus, in a range of about 50 megapascals (MPa) to 150 MPa, the second porosity less than the first porosity and the second initial tensile modulus greater than the first initial tensile modulus; and wherein either: the first sheet-like component is defined by a longitudinal dimension, a lateral dimension, and a thickness dimension, wherein the longitudinal dimension is greater than the lateral dimension and the thickness dimension, and wherein the first sheet-like component further comprises one or more longitudinal pathways extending along the longitudinal dimension of the first sheet-like component, and/or the plurality of pores have sizes between about 20 microns and 400 microns and at least some of the plurality of pores extend parallel to a longitudinal axis of the first sheet-like component, and/or the first sheet-like component is configured to degrade in tensile strength from a first initial tensile strength at a first rate and the second sheet-like component is configured to degrade in tensile strength from a second initial tensile strength at a second rate different from the first rate. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to DINAH BARIA whose telephone number is (571)270-1973. The examiner can normally be reached Monday - Friday 10am - 5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jerrah Edwards can be reached at 408-918-7557. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DINAH BARIA/Primary Examiner, Art Unit 3774
Read full office action

Prosecution Timeline

Jul 22, 2024
Application Filed
Sep 09, 2026
Non-Final Rejection mailed — §DP
Sep 23, 2026
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746114
NASAL IMPLANTS AND SYSTEMS AND METHOD OF USE
3y 2m to grant Granted Sep 29, 2026
Patent 12734028
SYSTEMS AND METHODS FOR SPECTACLE INDEPENDENCE USING REFRACTIVE INDEX WRITING WITH AN INTRAOCULAR LENS
3y 7m to grant Granted Sep 15, 2026
Patent 12714585
STENT, STENT KIT, AND STENT DELIVERY SYSTEM
3y 8m to grant Granted Aug 25, 2026
Patent 12708501
DILATING DEVICE AND METHOD FOR PROSTATIC URETHRA
3y 1m to grant Granted Aug 18, 2026
Patent 12697201
VASCULAR IMPLANT AND METHOD FOR THE PRODUCTION THEREOF
4y 9m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
99%
With Interview (+28.5%)
2y 9m (~6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 649 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month